Biopharmaceutical company GSK plc (LSE/NYSE: GSK) announced on Wednesday that the European Commission has approved a fully liquid version of Menveo, its meningococcal Group A, C, W-135, and Y conjugate vaccine (MenACWY).
This single-vial formulation, which eliminates the need for reconstitution, simplifies immunisation against invasive meningococcal disease (IMD) and is approved for individuals aged two years and older.
The approval follows two Phase IIb trials demonstrating comparable immunogenicity, tolerability and safety to the existing lyophilised/liquid version. This new presentation supports efficient vaccination workflows for a disease known for its severe, life-threatening complications. IMD remains a critical global health concern, with high mortality rates and significant long-term effects for survivors.
The original lyophilised Menveo formulation, approved in 2010, remains available. Menveo is authorised in over 60 countries and has delivered over 82 million doses globally, with more than 6 million distributed in Europe since 2017.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals